Treceți offline cu aplicația Player FM !
A Sit Down with Breakthrough T1D's (Formerly JDRF) CEO Aaron Kowalski
Manage episode 443032753 series 3331397
A Sit Down with Breakthrough T1D (Formerly JDRF) – Featuring Aaron Kowalski, CEO
TAKING CONTROL OF YOUR DIABETES® - THE PODCAST! ...With Expert Endocrinologists Living with T1D, Drs. Steven V. Edelman & Jeremy Pettus
This special edition of the Taking Control of Your Diabetes podcast is an enlightening conversation between three diabetes experts all living with type 1 diabetes themselves: Dr. Steve Edelman, Dr. Jeremy Pettus, and Dr. Aaron Kowalski, CEO of Breakthrough T1D (formerly JDRF) . They discuss recent research breakthroughs in type 1 diabetes, focusing on three main areas: improving lives through technology and medications, disease-modifying therapies to address the autoimmune nature of type 1 diabetes, and cellular replacement therapies. The conversation highlights advancements in hybrid closed-loop systems, emerging drugs for better glucose control, screening for early detection, and promising stem cell research that could lead to a cure. Dr. Kowalski expresses optimism about the future, suggesting that cell therapy products could be available within this decade, potentially allowing some people with type 1 diabetes to stop requiring insulin.
Key topics include:
- Who is Aaron Kowalski and how did he become the CEO of Breakthrough T1D?
- What is the history of JDRF, and why did the name change?
- What is the mission of Breakthrough T1D?
- The three main types of goals/research at Breakthrough T1D: Improving the lives of those with type 1 diabetes, Disease-modifying therapies, Сell replacement therapies
- What is the importance of getting screened for T1D?
- How has technology for diabetes evolved?
- Will there ever be a cure for T1D?
- How can cellular replacement therapies help us find a cure for T1D?
Breakthrough T1D (formerly JDRF) accelerates life-changing breakthroughs for type 1 diabetes through multiple approaches. They fund and drive research in three main areas: improving daily life with diabetes through technology and medication advancements, developing disease-modifying therapies to address the autoimmune nature of type 1 diabetes, and advancing cell replacement therapies, particularly stem cell-derived islet cells. Additionally, they focus on screening initiatives to identify at-risk individuals, advocate for broader access to treatments and clinical trials, educate the community and healthcare providers about new developments, and partner with pharmaceutical companies and research institutions. Their overarching goal is to drive towards curing type 1 diabetes while simultaneously making everyday life easier for those living with the condition.
Follow Breakthrough T1D:
Instagram: https://www.instagram.com/breakthrought1dhq/
Facebook: https://www.facebook.com/breakthrought1dhq
X: https://x.com/BreakthroughT1D
Linkedin: https://www.linkedin.com/company/breakthrought1d/posts/?feedView=all
Visit Breakthrough T1D Website: https://www.breakthrought1d.org/
Connect with Aaron Kowalski, CEO of Breakthrough T1D: https://www.linkedin.com/in/aaron-kowalski-3221a35/
Useful links to discover:
TCOYD Podcast - Why Everyone Should Screen for Type 1: https://tcoydthepodcast.transistor.fm/55
TCOYD Article: https://tcoyd.org/2024/06/an-endocrinologists-journey-helping-with-people-living-with-type-1-diabetes/
Visit TCOYD's Website for more diabetes edutainment for people living with diabetes: https://tcoyd.org/
**Tune in for two new episodes each month! Like what you hear and want to help us grow? Please rate and review this podcast so we can reach more people living with diabetes!**
Follow our social media channels to empower yourself with the essential areas of diabetes knowledge led by two endocrinologists living with type 1 diabetes:
Facebook: https://www.facebook.com/TCOYD/
Instagram: https://www.instagram.com/tcoyd/
YouTube: https://www.youtube.com/channel/UC4WWhIDg18gP9ZC-IeqmYNQ
64 episoade
Manage episode 443032753 series 3331397
A Sit Down with Breakthrough T1D (Formerly JDRF) – Featuring Aaron Kowalski, CEO
TAKING CONTROL OF YOUR DIABETES® - THE PODCAST! ...With Expert Endocrinologists Living with T1D, Drs. Steven V. Edelman & Jeremy Pettus
This special edition of the Taking Control of Your Diabetes podcast is an enlightening conversation between three diabetes experts all living with type 1 diabetes themselves: Dr. Steve Edelman, Dr. Jeremy Pettus, and Dr. Aaron Kowalski, CEO of Breakthrough T1D (formerly JDRF) . They discuss recent research breakthroughs in type 1 diabetes, focusing on three main areas: improving lives through technology and medications, disease-modifying therapies to address the autoimmune nature of type 1 diabetes, and cellular replacement therapies. The conversation highlights advancements in hybrid closed-loop systems, emerging drugs for better glucose control, screening for early detection, and promising stem cell research that could lead to a cure. Dr. Kowalski expresses optimism about the future, suggesting that cell therapy products could be available within this decade, potentially allowing some people with type 1 diabetes to stop requiring insulin.
Key topics include:
- Who is Aaron Kowalski and how did he become the CEO of Breakthrough T1D?
- What is the history of JDRF, and why did the name change?
- What is the mission of Breakthrough T1D?
- The three main types of goals/research at Breakthrough T1D: Improving the lives of those with type 1 diabetes, Disease-modifying therapies, Сell replacement therapies
- What is the importance of getting screened for T1D?
- How has technology for diabetes evolved?
- Will there ever be a cure for T1D?
- How can cellular replacement therapies help us find a cure for T1D?
Breakthrough T1D (formerly JDRF) accelerates life-changing breakthroughs for type 1 diabetes through multiple approaches. They fund and drive research in three main areas: improving daily life with diabetes through technology and medication advancements, developing disease-modifying therapies to address the autoimmune nature of type 1 diabetes, and advancing cell replacement therapies, particularly stem cell-derived islet cells. Additionally, they focus on screening initiatives to identify at-risk individuals, advocate for broader access to treatments and clinical trials, educate the community and healthcare providers about new developments, and partner with pharmaceutical companies and research institutions. Their overarching goal is to drive towards curing type 1 diabetes while simultaneously making everyday life easier for those living with the condition.
Follow Breakthrough T1D:
Instagram: https://www.instagram.com/breakthrought1dhq/
Facebook: https://www.facebook.com/breakthrought1dhq
X: https://x.com/BreakthroughT1D
Linkedin: https://www.linkedin.com/company/breakthrought1d/posts/?feedView=all
Visit Breakthrough T1D Website: https://www.breakthrought1d.org/
Connect with Aaron Kowalski, CEO of Breakthrough T1D: https://www.linkedin.com/in/aaron-kowalski-3221a35/
Useful links to discover:
TCOYD Podcast - Why Everyone Should Screen for Type 1: https://tcoydthepodcast.transistor.fm/55
TCOYD Article: https://tcoyd.org/2024/06/an-endocrinologists-journey-helping-with-people-living-with-type-1-diabetes/
Visit TCOYD's Website for more diabetes edutainment for people living with diabetes: https://tcoyd.org/
**Tune in for two new episodes each month! Like what you hear and want to help us grow? Please rate and review this podcast so we can reach more people living with diabetes!**
Follow our social media channels to empower yourself with the essential areas of diabetes knowledge led by two endocrinologists living with type 1 diabetes:
Facebook: https://www.facebook.com/TCOYD/
Instagram: https://www.instagram.com/tcoyd/
YouTube: https://www.youtube.com/channel/UC4WWhIDg18gP9ZC-IeqmYNQ
64 episoade
Toate episoadele
×Bun venit la Player FM!
Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.